These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 9918582

  • 1. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

  • 2. The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin.
    Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW.
    Endocrinology; 1998 Feb; 139(2):566-70. PubMed ID: 9449626
    [Abstract] [Full Text] [Related]

  • 3. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 4. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 5. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
    Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF.
    J Pharmacol Exp Ther; 2004 Sep 15; 310(3):1027-34. PubMed ID: 15115804
    [Abstract] [Full Text] [Related]

  • 11. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors.
    Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE.
    J Comp Neurol; 1999 Dec 20; 415(3):285-312. PubMed ID: 10553117
    [Abstract] [Full Text] [Related]

  • 12. Microinjection of urocortin into the rat nucleus tractus solitarii decreases arterial blood pressure.
    Yamazaki T, Waki H, Kohsaka A, Nakamura T, Cui H, Yukawa K, Maeda M.
    Auton Neurosci; 2008 Nov 03; 142(1-2):51-4. PubMed ID: 18804421
    [Abstract] [Full Text] [Related]

  • 13. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
    Okada R, Miller MF, Yamamoto K, De Groef B, Denver RJ, Kikuyama S.
    Gen Comp Endocrinol; 2007 Feb 03; 150(3):437-44. PubMed ID: 17188689
    [Abstract] [Full Text] [Related]

  • 14. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.
    Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C.
    Nature; 1995 Nov 16; 378(6554):287-92. PubMed ID: 7477349
    [Abstract] [Full Text] [Related]

  • 15. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
    Klose J, Fechner K, Beyermann M, Krause E, Wendt N, Bienert M, Rudolph R, Rothemund S.
    Biochemistry; 2005 Feb 08; 44(5):1614-23. PubMed ID: 15683245
    [Abstract] [Full Text] [Related]

  • 16. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats.
    Million M, Maillot C, Saunders P, Rivier J, Vale W, Taché Y.
    Am J Physiol Gastrointest Liver Physiol; 2002 Jan 08; 282(1):G34-40. PubMed ID: 11751155
    [Abstract] [Full Text] [Related]

  • 17. Effects of urocortin, corticotropin-releasing factor (CRF) receptor agonist, and astressin, CRF receptor antagonist, on the sleep-wake pattern: analysis by radiotelemetry in conscious rats.
    Uchida M, Suzuki M, Shimizu K.
    Biol Pharm Bull; 2007 Oct 08; 30(10):1895-7. PubMed ID: 17917258
    [Abstract] [Full Text] [Related]

  • 18. Corticotropin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides.
    Perrin MH, Haas Y, Rivier JE, Vale WW.
    Endocrinology; 1986 Mar 08; 118(3):1171-9. PubMed ID: 3004898
    [Abstract] [Full Text] [Related]

  • 19. Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats.
    Czimmer J, Million M, Taché Y.
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar 08; 290(3):G511-8. PubMed ID: 16223946
    [Abstract] [Full Text] [Related]

  • 20. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
    Lawrence AJ, Krstew EV, Dautzenberg FM, Rühmann A.
    Br J Pharmacol; 2002 Jul 08; 136(6):896-904. PubMed ID: 12110614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.